Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

OP09

Sigma-Aldrich

Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801)

liquid, clone PAb1801, Calbiochem®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12352203
NACRES:
NA.43

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

PAb1801, monoclonal

form

liquid

contains

≤0.1% sodium azide as preservative

species reactivity

human

should not react with

mouse, rat

manufacturer/tradename

Calbiochem®

storage condition

do not freeze

isotype

IgG1

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... TP53(7157)

General description

Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 Ag14 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A-431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801) is validated for use in Frozen Sections, Gel Shift, Immunoblotting, IP, Paraffin Sections for the detection of p53 (Ab-2) (Pantropic).

Immunogen

Epitope: within amino acids 46-55 of human p53
Human
a human p53 fusion protein

Application

Frozen Sections (5 µg/ml)

Gel Shift (see comments)

Immunoblotting (2.5 µg/ml)

Immunoprecipitation (1 µg/sample)

Paraffin Sections (5 µg/ml, pepsin, trypsin, or heat pre-treatment required)

Packaging

Please refer to vial label for lot-specific concentration.

Warning

Toxicity: Standard Handling (A)

Physical form

In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.

Analysis Note

Negative Control
SK-OV-3 cells or normal skin
Positive Control
A431 cells or breast carcinoma tissue

Other Notes

El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991. Cancer Res.51, 6304.
Wild-type p53 has a short half-life and is present in low amounts in cells. For immunoprecipitation, increasing the amount of sample to be immunoprecipitated and applied to the gel may help visualize wild-type p53; short incubation times with 35S-Met (≤ 1 h) will help reduce background. For immunoblots of wild-type p53, maximize sensitivity by preconcentrating samples by immunoprecipitation with Cat. No. OP09, then immunoblot using Cat. No. PC35 and chemiluminescent detection. For a gel shift assay, use Cat. No. OP09L and resuspend in 100 µl buffer. Antibody should be titrated for optimal results in individual systems.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Storage Class

10 - Combustible liquids

wgk_germany

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

James G Jackson et al.
Cancer cell, 21(6), 793-806 (2012-06-16)
Studies on the role of TP53 mutation in breast cancer response to chemotherapy are conflicting. Here, we show that, contrary to dogma, MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinical response compared to tumors with wild-type p53. Doxorubicin-treated
Timothy C Hallstrom et al.
Proceedings of the National Academy of Sciences of the United States of America, 100(19), 10848-10853 (2003-09-05)
Previous work has demonstrated a role for the E2F1 gene product in signaling apoptosis, both as a result of the deregulation of the Rb/E2F pathway as well as in response to DNA damage. We now show that the ability of
N Shinoura et al.
British journal of cancer, 86(4), 587-595 (2002-03-01)
Mutation of the p53 gene plays a critical role in the development of cancer and response to cancer therapy. To analyze the mechanism of cancer development and to improve cancer therapy, it is important to assess which genes are downstream
Shou-Ching Tang et al.
Breast cancer research and treatment, 84(3), 203-213 (2004-03-18)
BAG-1, a recently identified anti-apoptotic protein, is overexpressed in the majority of invasive breast carcinomas. Overexpression of BAG-1 is important for both multi-step oncogenesis and resistance of cancer cells to apoptosis induced by DNA-damaging alkylating agents. BAG-1 protein species are
Timothy Budden et al.
Oncotarget, 7(38), 60940-60953 (2016-08-04)
UVB exposure leads to DNA damage, which when unrepaired induces C>T transitions. These mutations are found throughout the melanoma genome, particularly in non-transcribed regions. The global genome repair (GGR) branch of nucleotide excision repair (NER) is responsible for repairing UV-induced

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico